Alprostadil
- Generic Name
- Alprostadil
- Brand Names
- Caverject, Edex, Muse, Prostin Vr
- Drug Type
- Small Molecule
- Chemical Formula
- C20H34O5
- CAS Number
- 745-65-3
- Unique Ingredient Identifier
- F5TD010360
- Background
Alprostadil is a chemically-identical synthetic form of prostaglandin E1 (PGE1), a potent vasodilator produced endogenously. In 1996, the FDA approved the use of alprostadil, administered either with an intracavernosal injection or an intraurethral suppository, for the treatment of erectile dysfunction, and it is used in men for whom oral treatment is either...
- Indication
Alprostadil is indicated for palliative, not definitive, therapy to temporarily maintain the patency of the ductus arteriosus until corrective or palliative surgery can be performed in neonates who have congenital heart defects and who depend upon the patent ductus for survival. It is also indicated for the treatment of erectile dysfunction due to neurogenic...
- Associated Conditions
- Erectile Dysfunction, Patent Ductus Arteriosus (PDA), Raynaud's Phenomenon
- Associated Therapies
- -
Effects of Prostaglandin E1 Treatment on Pyloric Wall in Newborns
- Conditions
- Interventions
- First Posted Date
- 2020-08-03
- Last Posted Date
- 2020-08-03
- Lead Sponsor
- Hacettepe University
- Target Recruit Count
- 20
- Registration Number
- NCT04496050
- Locations
- 🇹🇷
Hacettepe University, Ankara, Turkey
Alprostadil as an Adjuvant Therapy With Indirect Angiosomal Revascularization in Critical Limb Ischemia.
- Conditions
- First Posted Date
- 2020-03-18
- Last Posted Date
- 2020-03-20
- Lead Sponsor
- Assiut University
- Target Recruit Count
- 30
- Registration Number
- NCT04312555
The Comparative Effectiveness of Alprostadil,Sodium Ferulate and Dopamine in Pediatric Acute Kidney Injury
- Conditions
- Interventions
- First Posted Date
- 2019-03-27
- Last Posted Date
- 2019-03-27
- Lead Sponsor
- Shengjing Hospital
- Target Recruit Count
- 300
- Registration Number
- NCT03892447
- Locations
- 🇨🇳
Shenjing Hospital, Shenyang, Liaoning, China
Efficacy of Intracoronary Infusion of Different Medicine in STEMI Patients With CSFP
- Conditions
- Interventions
- First Posted Date
- 2017-09-28
- Last Posted Date
- 2020-03-12
- Lead Sponsor
- RenJi Hospital
- Target Recruit Count
- 57
- Registration Number
- NCT03296670
- Locations
- 🇨🇳
Ren Ji Hospital Afflited to School of Medicine, Shanghai Jiao Tong University, ShangHai, China
Efficacy of Intracoronary Infusion of Different Medicine in STEMI Patients Undergoing Primary PCI
- Conditions
- Interventions
- First Posted Date
- 2017-08-17
- Last Posted Date
- 2017-08-17
- Lead Sponsor
- RenJi Hospital
- Target Recruit Count
- 600
- Registration Number
- NCT03252665
- Locations
- 🇨🇳
Ren Ji Hospital Afflited to School of Medicine, Shanghai Jiao Tong University, ShangHai, China
Study on the Efficacy of Alprostadil Injection in Patients With Acute Ischemic Stroke
- First Posted Date
- 2017-08-17
- Last Posted Date
- 2024-04-01
- Lead Sponsor
- The First Hospital of Jilin University
- Target Recruit Count
- 950
- Registration Number
- NCT03252626
Blood Flow Change After Free Flap Surgery in Diabetic Patients
- Conditions
- First Posted Date
- 2017-01-23
- Last Posted Date
- 2018-11-30
- Lead Sponsor
- Asan Medical Center
- Target Recruit Count
- 44
- Registration Number
- NCT03027219
- Locations
- 🇰🇷
Asan Medical Center, Seoul, Korea, Republic of
PGE1 as Additive Anticoagulant in ECMO-Therapy
- Conditions
- Interventions
- First Posted Date
- 2016-09-09
- Last Posted Date
- 2022-02-09
- Lead Sponsor
- Thomas Staudinger
- Target Recruit Count
- 50
- Registration Number
- NCT02895373
- Locations
- 🇦🇹
Medical University of Vienna, Department of Medicine I, Intensive Care Unit, Vienna, Austria
Study of Acute Peripheral Vascular Effects, Safety and Tolerability in Subjects With Raynaud's Phenomenon Secondary to Systemic Sclerosis
- Conditions
- Interventions
- First Posted Date
- 2014-08-29
- Last Posted Date
- 2016-03-22
- Target Recruit Count
- 35
- Registration Number
- NCT02228850
- Locations
- 🇺🇸
Diagnamics, Inc., Encinitas, California, United States
🇺🇸University of Michigan Scleroderma Program - Division of Rheumatology/Dept. of Internal Medicine, Ann Arbor, Michigan, United States
🇺🇸Cleveland Clinic, Cleveland, Ohio, United States
Efficacy, Safety and Satisfaction of VITAROS (Transdermal Topical Alprostadil) in Men With Erectile Dysfunction
- First Posted Date
- 2013-01-28
- Last Posted Date
- 2014-03-04
- Lead Sponsor
- Lawson Health Research Institute
- Registration Number
- NCT01776320
- Locations
- 🇨🇦
St. Joseph's Health Care London, London, Ontario, Canada
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.